SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

3235-0104 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Seely Lynn Red		. Date of Event equiring Staten Month/Day/Year 0/26/2016	nent	3. Issuer Name and Ticker or Trading Symbol <u>Myovant Sciences Ltd.</u> [MYOV]						
(Last) (First) C/O MYOVANT SCIENCE 320 WEST 37TH STREET (Street) NEW YORK NY (City) (State)					tionship of Reporting Perso all applicable) Director Officer (give title below) Principal Executive	10% Owne Other (spe below)	er .	(Mont	th/Day/Year) lividual or Joint cable Line) Form filed by	te of Original Filed Group Filing (Check / One Reporting Person / More than One erson
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4)				4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Shares					1,128,222 ⁽¹⁾	D				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
Expira		Expiration Da	Date Exercisable and xpiration Date /onth/Day/Year)		3. Title and Amount of Securit Underlying Derivative Securit		4. Conversion	sion cise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Evaluation of Pernonces:		Date Exercisable	Expiration Date	n Title		Amount or Number of Shares	Price of Derivati Securit	ive	Direct (D) or Indirect (I) (Instr. 5)	

1. 1/4th of the shares shall vest and become non-forfeitable on May 31, 2017; the balance of the shares shall vest and become non-forfeitable in a series of twelve (12) successive equal quarterly installments measured from May 31, 2017, subject to the Reporting Person providing continuous service to the Issuer on each such date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

/s/Alison Haggerty, Attorney-

in-Fact

10/26/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

(For Executing Forms 3, 4 and 5)

Know all by these presents, that the undersigned hereby constitutes and appoints each of Frank Rahmani, John McKenna and Alison Haggerty of Cooley LLP, and Frank Karbe, Interim Chief Financial Officer of Myovant Sciences, Inc., a wholly-owned subsidiary of Myovant Sciences Ltd. (the "Company"), signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

(1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC") Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company;

(2) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Forms 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such forms with the SEC and any stock exchange, self-regulatory association or any similar authority; and

(3) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company, or any of its subsidiaries, or Cooley LLP, as applicable.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Date: October 14, 2016

By: /s/Lynn Seely Lynn Seely, M.D.